Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $15.71

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $15.7143.

Several equities research analysts have commented on ALT shares. Leerink Partners initiated coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price target on the stock. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Tuesday, June 2nd. Citizens Jmp dropped their target price on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th.

Institutional Trading of Altimmune

Several large investors have recently made changes to their positions in ALT. SBI Securities Co. Ltd. grew its position in Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Altimmune by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after buying an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC raised its holdings in shares of Altimmune by 10.4% in the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after buying an additional 2,500 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after buying an additional 2,748 shares during the period. Finally, Deutsche Bank AG raised its holdings in shares of Altimmune by 4.0% in the 4th quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after buying an additional 3,047 shares during the period. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Price Performance

Shares of NASDAQ ALT opened at $2.93 on Friday. The business’s 50 day moving average price is $2.91 and its 200 day moving average price is $3.59. The firm has a market cap of $569.80 million, a P/E ratio of -3.15 and a beta of 0.25. Altimmune has a 52 week low of $2.56 and a 52 week high of $6.44. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. On average, sell-side analysts expect that Altimmune will post -0.69 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.